In the world of life sciences, we’re standing at the edge of a transformative era. The last decade has seen machine learning carve out significant advancements, enabling experts to predict protein interactions and design molecules with unprecedented precision. 

The financing, led by ICONIQ Growth, enables Causaly to accelerate innovation and drive increased adoption of its category-leading AI platform to modernize scientific research.

Gastrointestinal (GI) stromal tumors are a rare form of soft tissue sarcoma of the digestive system, primarily affecting the stomach and small intestine. In the US, approximately 6000 new cases of GI stromal tumors are diagnosed each year. Despite their rarity, these tumors are the most prevalent mesenchymal tumors of the GI tract.

Nonalcoholic steatohepatitis (NASH) is a progressive liver condition characterized by inflammation, cell damage and fibrosis. NASH affects up to 6% of the United States population, and is becoming a significant health concern. Statistics indicate that up to 10% of individuals diagnosed with NASH will develop cirrhosis, causing permanent liver damage.

Alzheimer’s disease (AD) is the most prevalent form of dementia. An estimated 6.5 million Americans aged 65 and older are living with Alzheimer’s dementia, a figure which is projected to soar to around 14 million by 2060. Current treatments only offer temporary symptomatic relief, highlighting the importance of AD research.

Chronic Obstructive Pulmonary Disease (COPD) is a life-threatening respiratory condition caused by airway obstruction. It ranks among the top global causes of death, with over 200 million cases and 3 million deaths reported in 2019.

Diabetes is a complex metabolic disorder which disrupts the balance of blood sugar in the body, affecting over 400 million people worldwide.¹ According to the World Health Organization (WHO), around 1.5 million deaths each year are directly attributable to diabetes, highlighting the critical need for research into this disease.

Since the 1950s, more than 500 biomarkers for SCD have been reported in the literature, according to Causaly data. Comparing this to more common blood diseases such as leukemia, which has over 10x more biomarkers reported, highlights the significant unmet need in the rare disease research.

Dive into groundbreaking research on Renal Cell Cancer, the most common kidney cancer in adults. Our blog explores innovative strategies for target identification, prioritization, and how these contribute to preventing and tackling this disease.

As we celebrate World MS Day on 30th May 2023, it’s a great opportunity to reflect on the significant strides that have been made in MS research over the past 5 years.

Causaly cofounders Yiannis Kiachopoulos and Artur Saudabayev hosted a webinar, “From AI to Impact”, in April 2023, exploring the transformative power of AI and GPT applications in early drug discovery. During this captivating session, they demonstrated how Causaly combines visual evidence with high precision knowledge graphs to answer complex research questions in mechanistic biology.   

Two targets were chosen for their novelty – transcription factor CEBPB and transport protein MX2, both reported to be associated to Lupus in 2022.

Toll-like receptor 7 (TLR7) has long been associated with the autoimmune disease, lupus. Genetic polymorphisms that result in higher TLR7 expression are associated with increased risk of developing lupus. Aberrant signaling from the protein, which senses single-stranded RNA viruses, is thought to be a mechanism driving the disease: TLR7 drives B cells to produce ‘auto-antibodies’. […]

Lupus is an autoimmune disease which affects about 1 in 1000 people, which commonly causes joint pain, skin rashes and tiredness.

Biomarkers 2023 was held in Manchester, UK on the 27th and 28th of February. The event brought together a diverse group of experts, across pharma, biotech, and academic institutions.

At Causaly, we stay close to the developments in the foundational natural language processing technologies and broader AI to understand where we stand with both academic and industrial state-of-the-art.

It has been well documented that only 1 out of 10 compounds that enter clinical trials makes it to market¹. That is an astonishing 90% failure rate. It is hard to imagine hiring a lawyer or doctor or any professional who fails so often. Yet in our industry, it remains the norm.

Being able to stay up to date with scientific data and efficiently extracting insights is critical to drug R&D – but currently it is a manual, time-consuming process

On June 9th – 10th 2022, over 400 pharma leaders came to Berlin to take part in Discovery Europe.

It is widely recognized that the Scientific Method is fundamental for discovering new medicines. We’re all familiar with the process: a researcher poses a question, such as what causes a specific disease, then gathers all relevant information that is known about their question. Upon digesting this information, they formulate a hypothesis and design experiments to […]